NCT00042952 2013-01-17Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerNational Cancer Institute (NCI)Phase 2 Terminated32 enrolled